Showing 421 - 440 results of 145,317 for search '(( a ((a decrease) OR (linear decrease)) ) OR ( a ((largest decrease) OR (greater decrease)) ))', query time: 0.87s Refine Results
  1. 421
  2. 422
  3. 423
  4. 424
  5. 425

    HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial by Anita Y.M. Kwan (11868016)

    Published 2022
    “…</p> <p><b>Conclusions:</b> Dulaglutide 1.5 mg treatment was statistically associated with a long-lasting decrease in HbA1c over 72 months, irrespective of baseline duration of diabetes, microvascular disease, and BMI.…”
  6. 426
  7. 427
  8. 428
  9. 429

    Decreasing fatty acid saturation suppresses Δ<i>yhdP</i> Δ<i>fadR</i> cold sensitivity. by Ashutosh K. Rai (18874704)

    Published 2024
    “…<p><b>(A-C)</b> Lipids were extracted from cells grown to OD<sub>600</sub> 0.2 at 42°C then shifted to 30°C for 2 hours before harvest. …”
  10. 430
  11. 431
  12. 432
  13. 433

    Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

    Published 2019
    “…<p><b>A.</b> Quantitative RT-PCR showing the expression of <i>clk</i>, <i>per</i> and <i>tim</i>. …”
  14. 434

    <b>Predictors of initial and sustained glycemic and weight response to tirzepatide: a post hoc analysis of SURPASS-4</b> by Ewan R. Pearson (157520)

    Published 2025
    “…Greater decrease in LDL-cholesterol to 52 weeks predicted maintained weight loss. …”
  15. 435
  16. 436
  17. 437
  18. 438
  19. 439

    Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58 by Avivit Cahn (10072991)

    Published 2022
    “…Dapagliflozin led to a decrease in the risk of CVD/HHF, HHF and the cardiorenal outcome vs. placebo with no heterogeneity by baseline HbA1c (P-interaction >0.05).…”
  20. 440